RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

(2022) Brian A. Bergmark et al.   CIRCULATION

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

(2022) Xiaozhi Hu et al.   JOURNAL OF NANOBIOTECHNOLOGY

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

(2022) Aruna Das Pradhan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3

(2021) Gerald F Watts et al.   Future Cardiology

Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi

(2020) Andrew A. Butler et al.   JOURNAL OF LIPID RESEARCH

Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

(2020) Rene C. Adam et al.   JOURNAL OF LIPID RESEARCH

Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias

(2020) Julius L. Katzmann et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

(2020) Daniel Gaudet et al.   EUROPEAN HEART JOURNAL

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk

(2019) Sander Kersten   CURRENT OPINION IN LIPIDOLOGY

Personalized Medicine for Dyslipidemias by RNA Interference-Mediated Reductions in Apolipoprotein C3 or Angiopoietin-Like Protein 3

(2019) So C. Wong et al.   Journal of Clinical Lipidology

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

(2019) Zahid Ahmad et al.   CIRCULATION

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles

(2019) Deepak L. Bhatt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical review on triglycerides

(2019) Ulrich Laufs et al.   EUROPEAN HEART JOURNAL

Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol

(2018) Yu-Xin Xu et al.   ATHEROSCLEROSIS

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

(2017) Nathan O. Stitziel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Angiopoietin-like 3 in lipoprotein metabolism

(2017) Sander Kersten   Nature Reviews Endocrinology

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

(2017) Mark J. Graham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin

(2017) Robert P. Giugliano et al.   JAMA Cardiology

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

(2016) Janki Patel et al.   Therapeutic Advances in Gastroenterology

Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease

(2015) Simon Barquera et al.   ARCHIVES OF MEDICAL RESEARCH

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys

(2015) Viktoria Gusarova et al.   JOURNAL OF LIPID RESEARCH

Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis

(2013) Ilenia Minicocci et al.   JOURNAL OF LIPID RESEARCH

Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia

(2010) Kiran Musunuru et al.   NEW ENGLAND JOURNAL OF MEDICINE